Business Standard

Shilpa Medicare to make drug substance for Cadila's ZyCoV-D vaccine

ZyCoV-D is the world's first approved DNA vaccine, and the first Covid-19 vaccine in India to be approved for use in adolescents 12 years and above

Cadila Healthcare
Premium

Cadila Healthcare

Sohini Das Mumbai
Hyderabad’s Shilpa Medicare will make the drug substance (raw material) for Cadila Healthcare’s DNA plasmid vaccine ZyCoV-D at its Dharwad facility. ZyCoV-D is the world’s first approved DNA vaccine, and the first Covid-19 vaccine in India to be approved for use in adolescents 12 years and above.

The volumes, however, have not been disclosed at the moment. Under the agreement, Shilpa Biologicals, a subsidiary of Shilpa Medicare, will manufacture the drug substance of the vaccine, while Zydus will do the filling-packaging and distribution of the vaccine.

In a notification to the stock exchanges both the firms said that Shilpa Biologicals

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Sep 24 2021 | 4:09 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com